Results 51 to 60 of about 562,472 (163)
Journal of Sleep Research, EarlyView.Network Analysis in Central Disorders of Hypersomnolence: Insight Into Relationships Between Symptoms, Mental Health, and Quality of Life. ABSTRACT In the central disorders of hypersomnolence (CDH) narcolepsy types 1 and 2 (NT1, NT2) and idiopathic hypersomnia (IH), mental health problems are highly prevalent, and quality of life is decreased.
Denise Bijlenga +4 more
wiley +1 more source
Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance–Adams Syndrome
Tremor and Other Hyperkinetic Movements, 2019 Background: Treatment of posthypoxic myoclonus (PHM) can be a challenge in patients not responsive to first-line medications. PMH is a rare condition that has a dramatic impact on patients’ quality of life. Refractory cases are not uncommon. Case report:
Giulietta M. Riboldi, Steven J. Frucht
doaj +1 more source
Journal of Sleep Research, EarlyView.Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein +10 more
wiley +1 more source
Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy
, 2017 This post hoc analysis evaluated the dose-related effects of sodium oxybate on sleep continuity and nocturnal sleep quality in patients with narcolepsy-cataplexy.
Dauvilliers, Yves +5 more
core +1 more source
The use of medications approved for alcohol use disorders in Italy
Frontiers in Public Health, 2023 BackgroundItaly has the highest per capita alcohol consumption among European countries. Several pharmacological treatments for alcohol use disorders (AUDs) are currently available in Italy, but no consumption data are available.
Filomena Fortinguerra +2 more
doaj +1 more source
Assessing mortality risk in narcolepsy: Evidence from population studies
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 3, September 2026.Abstract Narcolepsy is a chronic neurologic sleep disorder associated with excessive daytime sleepiness, cataplexy, and a higher prevalence of cardiovascular and psychiatric comorbidities. While these factors may predispose individuals to adverse events, observational studies evaluating mortality in narcolepsy have yielded inconsistent results.
Nawris Alhassan +2 more
wiley +1 more source
Sodium Oxybate: A Cause of Extreme Involuntary Weight Loss in a Young Lady
Case Reports in Medicine, 2019 We present a case of a young lady with extreme involuntary weight loss and alarming constitutional symptoms found ultimately to be all due to a single medication’s side effects.
Michael G. Noujaim +2 more
doaj +1 more source
Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1
Internal Medicine Journal, Volume 56, Issue 9, Page 1641-1643, September 2026.Abstract A clinical diagnosis of narcolepsy type 1 can be challenging, particularly in relation to cataplexy. Despite its specificity, cerebrospinal fluid (CSF) orexin testing is under‐utilised in Australasia. We describe the use of CSF orexin testing in 15 clinically indicated patients from two sleep centres, highlighting its utility in the ...
Mario Fernando +8 more
wiley +1 more source
Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate
Frontiers in Neurology, 2014 Aim: Hypnagogic and hypnopompic hallucinations are characteristic symptoms of narcolepsy, as are excessive daytime sleepiness, cataplexy and sleep paralysis.
Tomi eSarkanen +7 more
doaj +1 more source
Journal of Sleep Research, Volume 35, Issue 4, August 2026.Study overview and clustering results in the iSPHYNCS cohort. Participant demographics are summarized in a baseline table. Questionnaire data and metadata were processed through an unsupervised clustering pipeline. A Sankey plot illustrates individual assignment across clusters by diagnostic group.
Rafael Morand +19 more
wiley +1 more source